Cancer Clinical Trials
This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.
Breast Cancer Radiation Study |
|---|
|
Trial Name: Name of Trial: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer Protocol ID: RTOG 0413 / NSABP B-39 Eligibility: Women with stage 0 (DCIS), I or II breast cancer. If stage II, tumor size must be < 3.0 cm.
Surgical treatment of the breast must have been a lumpectomy and must have been performed prior to study entry. The margins of the resected specimen must be histologically free of tumor (DCIS and invasive).
Women with invasive breast cancer are required to have axillary staging which can include sentinel biopsy alone (if sentinel node is negative), sentinel node biopsy followed by axillary dissection or sampling with a minimum total of 6 axillary nodes (if sentinel node is positive), or axillary dissection alone (with minimum of 6 axillary nodes), For woman to be eligible, she can have no more than 3 axillary nodes that are histologically positive. Axillary staging is not required for patients with DCIS.
Target lumpectomy cavity must be clearly delineated and the target lumpectomy cavity/whole breast reference volume must be < 30% based on the postoperative/pre-randomization CT scan.
Signed informed consent.
Women must be registered to the study within 42 days following the last surgery for breast cancer (lumpectomy, re-excision of margins, or axillary staging procedure).
Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters are NOT eligible
History of invasive breast cancer or DCIS are NOT eligible. (Patients with a history of LCIS treated by surgery alone are eligible.) Enrollment: About 3000 women will take part in this study. Benefits: Hopefully the information learned from this study will benefit other patients with breast cancer in the future.
Contact: These clinical trail overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical ResearchNurse, Beth Knetter at 715-847-2353 or 1-800-283-2881. Created: Nov 28, 2006 Updated: Jan 18, 2013 |